Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 31 | 2023 | 2362 | 5.430 |
Why?
|
Ticlopidine | 13 | 2022 | 895 | 2.490 |
Why?
|
Lipoprotein(a) | 7 | 2024 | 499 | 2.380 |
Why?
|
Anticholesteremic Agents | 9 | 2024 | 988 | 2.280 |
Why?
|
Myocardial Infarction | 36 | 2024 | 11891 | 2.170 |
Why?
|
Platelet Aggregation Inhibitors | 25 | 2024 | 3201 | 1.940 |
Why?
|
Benzaldehydes | 8 | 2018 | 59 | 1.760 |
Why?
|
Oximes | 8 | 2018 | 306 | 1.570 |
Why?
|
Atherosclerosis | 10 | 2024 | 3524 | 1.560 |
Why?
|
Purinergic P2Y Receptor Antagonists | 5 | 2022 | 379 | 1.530 |
Why?
|
Pyridines | 11 | 2021 | 2877 | 1.530 |
Why?
|
Hemorrhage | 12 | 2023 | 3604 | 1.280 |
Why?
|
Angina, Unstable | 5 | 2020 | 926 | 1.120 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2023 | 3333 | 1.100 |
Why?
|
Heart Failure | 23 | 2023 | 11835 | 1.060 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15740 | 1.050 |
Why?
|
Double-Blind Method | 24 | 2024 | 12412 | 1.010 |
Why?
|
Imines | 4 | 2012 | 34 | 1.000 |
Why?
|
Thiophenes | 5 | 2013 | 587 | 0.940 |
Why?
|
RNA, Small Interfering | 2 | 2024 | 3443 | 0.930 |
Why?
|
Cyclopropanes | 2 | 2016 | 431 | 0.920 |
Why?
|
Sex Characteristics | 5 | 2023 | 2627 | 0.900 |
Why?
|
Natriuretic Peptide, Brain | 11 | 2023 | 1705 | 0.880 |
Why?
|
Coronary Artery Disease | 14 | 2024 | 6661 | 0.880 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 688 | 0.850 |
Why?
|
Stroke | 14 | 2024 | 9945 | 0.830 |
Why?
|
Guilt | 1 | 2022 | 96 | 0.770 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.740 |
Why?
|
Coronary Restenosis | 2 | 2021 | 426 | 0.740 |
Why?
|
Lactones | 3 | 2019 | 319 | 0.740 |
Why?
|
Women | 2 | 2020 | 224 | 0.730 |
Why?
|
Calgranulin A | 1 | 2021 | 80 | 0.730 |
Why?
|
Calgranulin B | 1 | 2021 | 86 | 0.730 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2018 | 129 | 0.720 |
Why?
|
Phospholipases A | 2 | 2014 | 204 | 0.690 |
Why?
|
Judgment | 1 | 2022 | 273 | 0.670 |
Why?
|
Platelet Function Tests | 2 | 2021 | 303 | 0.650 |
Why?
|
Heptanoic Acids | 2 | 2014 | 347 | 0.630 |
Why?
|
Pravastatin | 2 | 2014 | 393 | 0.630 |
Why?
|
P-Selectin | 1 | 2021 | 600 | 0.620 |
Why?
|
Thrombolytic Therapy | 6 | 2013 | 2108 | 0.610 |
Why?
|
Piperazines | 5 | 2013 | 2520 | 0.610 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2013 | 296 | 0.590 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.590 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2023 | 1387 | 0.580 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2024 | 10829 | 0.580 |
Why?
|
Hypercholesterolemia | 2 | 2022 | 1155 | 0.580 |
Why?
|
Receptors, Thrombin | 3 | 2014 | 132 | 0.570 |
Why?
|
Secondary Prevention | 7 | 2019 | 1548 | 0.570 |
Why?
|
Cystatin C | 1 | 2018 | 270 | 0.570 |
Why?
|
Proton Pump Inhibitors | 3 | 2013 | 551 | 0.560 |
Why?
|
Glomerular Filtration Rate | 6 | 2022 | 2178 | 0.550 |
Why?
|
Thrombosis | 4 | 2024 | 3052 | 0.540 |
Why?
|
Drug-Eluting Stents | 2 | 2021 | 758 | 0.530 |
Why?
|
Glucosides | 1 | 2021 | 536 | 0.530 |
Why?
|
CD40 Ligand | 2 | 2021 | 522 | 0.520 |
Why?
|
Treatment Outcome | 36 | 2024 | 64947 | 0.510 |
Why?
|
Humans | 124 | 2024 | 760261 | 0.510 |
Why?
|
Diabetic Angiopathies | 3 | 2016 | 822 | 0.510 |
Why?
|
Peptide Fragments | 9 | 2023 | 5120 | 0.500 |
Why?
|
Death, Sudden, Cardiac | 3 | 2021 | 1572 | 0.490 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2017 | 196 | 0.490 |
Why?
|
Risk Assessment | 16 | 2021 | 24086 | 0.490 |
Why?
|
Galectin 3 | 2 | 2016 | 240 | 0.480 |
Why?
|
Platelet Activation | 4 | 2016 | 661 | 0.470 |
Why?
|
Pyrroles | 2 | 2014 | 1137 | 0.460 |
Why?
|
Coronary Disease | 4 | 2018 | 5993 | 0.460 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 942 | 0.460 |
Why?
|
Female | 81 | 2024 | 391011 | 0.450 |
Why?
|
Male | 75 | 2024 | 359413 | 0.450 |
Why?
|
Cholesterol, LDL | 8 | 2023 | 2422 | 0.450 |
Why?
|
Aspirin | 5 | 2022 | 3365 | 0.450 |
Why?
|
Adenosine Monophosphate | 1 | 2016 | 283 | 0.450 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2021 | 10340 | 0.430 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 864 | 0.420 |
Why?
|
Blood Platelets | 6 | 2023 | 2522 | 0.420 |
Why?
|
Middle Aged | 55 | 2024 | 220175 | 0.420 |
Why?
|
Blood Proteins | 2 | 2016 | 1172 | 0.420 |
Why?
|
Ischemia | 1 | 2021 | 1893 | 0.420 |
Why?
|
Aged | 52 | 2024 | 168995 | 0.420 |
Why?
|
Risk Factors | 35 | 2024 | 74269 | 0.420 |
Why?
|
Acetates | 1 | 2014 | 322 | 0.410 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 867 | 0.410 |
Why?
|
Thiazoles | 2 | 2021 | 1509 | 0.400 |
Why?
|
Dyspnea | 8 | 2008 | 1352 | 0.400 |
Why?
|
Electrocardiography | 4 | 2021 | 6413 | 0.390 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.390 |
Why?
|
Communication Barriers | 1 | 2014 | 415 | 0.380 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2009 | 1880 | 0.370 |
Why?
|
Women's Health | 2 | 2024 | 2057 | 0.370 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.360 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5201 | 0.360 |
Why?
|
Adenosine | 1 | 2015 | 833 | 0.360 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 694 | 0.350 |
Why?
|
Receptor, PAR-1 | 3 | 2019 | 114 | 0.350 |
Why?
|
Myocardial Revascularization | 3 | 2016 | 841 | 0.340 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 253 | 0.340 |
Why?
|
Purinergic P2 Receptor Antagonists | 1 | 2009 | 72 | 0.330 |
Why?
|
Oxytocin | 2 | 2024 | 401 | 0.330 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5640 | 0.320 |
Why?
|
Fibrinolytic Agents | 4 | 2024 | 2167 | 0.320 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1882 | 0.320 |
Why?
|
Indoles | 2 | 2014 | 1830 | 0.310 |
Why?
|
Kidney Diseases | 1 | 2019 | 2093 | 0.300 |
Why?
|
Interleukin-6 | 1 | 2017 | 3207 | 0.290 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12532 | 0.290 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6545 | 0.290 |
Why?
|
Platelet Aggregation | 4 | 2017 | 805 | 0.290 |
Why?
|
Warfarin | 1 | 2015 | 1516 | 0.270 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1520 | 0.260 |
Why?
|
Stents | 4 | 2022 | 3303 | 0.260 |
Why?
|
Recurrence | 5 | 2018 | 8487 | 0.250 |
Why?
|
Administration, Intranasal | 2 | 2024 | 471 | 0.250 |
Why?
|
Creatinine | 4 | 2022 | 1906 | 0.250 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 12602 | 0.250 |
Why?
|
Disease Management | 1 | 2016 | 2508 | 0.240 |
Why?
|
Genetic Pleiotropy | 2 | 2016 | 181 | 0.240 |
Why?
|
Health Status Disparities | 2 | 2024 | 1819 | 0.240 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1859 | 0.240 |
Why?
|
Dicarboxylic Acids | 1 | 2024 | 77 | 0.230 |
Why?
|
Sex Factors | 5 | 2021 | 10530 | 0.230 |
Why?
|
Coronary Thrombosis | 2 | 2019 | 486 | 0.230 |
Why?
|
Prognosis | 13 | 2023 | 29636 | 0.230 |
Why?
|
Renal Insufficiency | 2 | 2022 | 820 | 0.220 |
Why?
|
Troponin T | 3 | 2016 | 774 | 0.220 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3696 | 0.220 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5884 | 0.220 |
Why?
|
Drug Interactions | 3 | 2013 | 1426 | 0.210 |
Why?
|
Subtilisins | 1 | 2022 | 82 | 0.200 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2022 | 63 | 0.200 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12156 | 0.200 |
Why?
|
Anticoagulants | 3 | 2024 | 4896 | 0.200 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12281 | 0.200 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1293 | 0.200 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1935 | 0.190 |
Why?
|
Sleep | 1 | 2017 | 4746 | 0.190 |
Why?
|
Ceramides | 1 | 2022 | 200 | 0.180 |
Why?
|
Subtilisin | 1 | 2020 | 12 | 0.180 |
Why?
|
Pulmonary Embolism | 3 | 2023 | 2544 | 0.180 |
Why?
|
Myocardium | 1 | 2012 | 4688 | 0.170 |
Why?
|
Aortic Valve Stenosis | 2 | 2024 | 2064 | 0.170 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2023 | 192 | 0.170 |
Why?
|
Databases, Factual | 1 | 2015 | 8018 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2022 | 6499 | 0.160 |
Why?
|
Obesity | 4 | 2024 | 12915 | 0.160 |
Why?
|
Scavenger Receptors, Class B | 1 | 2018 | 84 | 0.160 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.160 |
Why?
|
Hospitalization | 5 | 2018 | 10761 | 0.150 |
Why?
|
Incidence | 5 | 2021 | 21378 | 0.150 |
Why?
|
Odds Ratio | 4 | 2017 | 9712 | 0.150 |
Why?
|
Phospholipids | 1 | 2022 | 789 | 0.150 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 22 | 0.150 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1866 | 0.150 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9196 | 0.150 |
Why?
|
Postoperative Complications | 1 | 2020 | 15680 | 0.150 |
Why?
|
Genetic Variation | 3 | 2017 | 6540 | 0.140 |
Why?
|
Thromboembolism | 1 | 2024 | 1016 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4900 | 0.140 |
Why?
|
Fatty Acids | 1 | 2024 | 1805 | 0.140 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2296 | 0.140 |
Why?
|
Patients | 1 | 2023 | 906 | 0.140 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 393 | 0.130 |
Why?
|
Adrenomedullin | 1 | 2016 | 85 | 0.130 |
Why?
|
C-Reactive Protein | 4 | 2016 | 3822 | 0.130 |
Why?
|
Quantitative Trait, Heritable | 1 | 2019 | 540 | 0.130 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 60 | 0.130 |
Why?
|
Models, Biological | 1 | 2012 | 9468 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2020 | 613 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 859 | 0.130 |
Why?
|
Placebos | 2 | 2021 | 1672 | 0.120 |
Why?
|
Troponin I | 3 | 2013 | 634 | 0.120 |
Why?
|
Neutrophils | 1 | 2008 | 3770 | 0.120 |
Why?
|
Atrial Natriuretic Factor | 1 | 2016 | 350 | 0.120 |
Why?
|
Placebo Effect | 1 | 2019 | 511 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 988 | 0.120 |
Why?
|
Glycopeptides | 1 | 2016 | 220 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 966 | 0.120 |
Why?
|
Risk | 3 | 2019 | 9629 | 0.120 |
Why?
|
Energy Intake | 2 | 2024 | 2128 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 988 | 0.120 |
Why?
|
Myocardial Ischemia | 2 | 2016 | 2161 | 0.120 |
Why?
|
Simvastatin | 1 | 2017 | 352 | 0.120 |
Why?
|
Immune System Diseases | 1 | 2016 | 258 | 0.110 |
Why?
|
Cardiology | 2 | 2024 | 1723 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 1521 | 0.110 |
Why?
|
Quantitative Trait Loci | 2 | 2019 | 2101 | 0.110 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3466 | 0.110 |
Why?
|
Galectins | 1 | 2016 | 282 | 0.110 |
Why?
|
Chest Pain | 2 | 2013 | 1106 | 0.110 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8058 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2021 | 58947 | 0.110 |
Why?
|
Predictive Value of Tests | 6 | 2011 | 15273 | 0.110 |
Why?
|
Peroxidase | 1 | 2016 | 604 | 0.110 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2716 | 0.110 |
Why?
|
Proprotein Convertases | 1 | 2013 | 97 | 0.100 |
Why?
|
Time Factors | 6 | 2020 | 40133 | 0.100 |
Why?
|
Dyslipidemias | 1 | 2020 | 895 | 0.100 |
Why?
|
Erythropoiesis | 1 | 2016 | 682 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1437 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 794 | 0.100 |
Why?
|
Stroke Volume | 2 | 2006 | 5513 | 0.100 |
Why?
|
Protein Precursors | 1 | 2016 | 1135 | 0.100 |
Why?
|
ROC Curve | 4 | 2008 | 3568 | 0.100 |
Why?
|
Language | 1 | 2021 | 1532 | 0.100 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 114 | 0.100 |
Why?
|
Kidney | 3 | 2022 | 7072 | 0.100 |
Why?
|
Genetic Loci | 2 | 2022 | 2618 | 0.100 |
Why?
|
Logistic Models | 4 | 2017 | 13311 | 0.100 |
Why?
|
Energy Metabolism | 2 | 2024 | 2869 | 0.090 |
Why?
|
Hypoglycemic Agents | 2 | 2021 | 3149 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15766 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 4 | 2024 | 17766 | 0.090 |
Why?
|
Analysis of Variance | 1 | 2018 | 6242 | 0.090 |
Why?
|
Data Mining | 1 | 2015 | 553 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2646 | 0.090 |
Why?
|
Phospholipases A2 | 2 | 2007 | 197 | 0.080 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 422 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2021 | 3293 | 0.080 |
Why?
|
Cat Diseases | 1 | 2008 | 31 | 0.080 |
Why?
|
Receptors, Cell Surface | 2 | 2008 | 2825 | 0.080 |
Why?
|
Oxalates | 1 | 2008 | 98 | 0.080 |
Why?
|
Urinary Calculi | 1 | 2008 | 91 | 0.080 |
Why?
|
Bifidobacterium | 1 | 2008 | 98 | 0.080 |
Why?
|
Serine Endopeptidases | 1 | 2013 | 1021 | 0.080 |
Why?
|
Leukocytes | 1 | 2016 | 2030 | 0.080 |
Why?
|
Dog Diseases | 1 | 2008 | 141 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1945 | 0.070 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1925 | 0.070 |
Why?
|
Research Design | 2 | 2015 | 6181 | 0.070 |
Why?
|
Lactobacillus | 1 | 2008 | 204 | 0.070 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2008 | 152 | 0.070 |
Why?
|
Acute Disease | 3 | 2007 | 7268 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6830 | 0.070 |
Why?
|
Necrosis | 1 | 2011 | 1612 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3870 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2415 | 0.070 |
Why?
|
Liver | 1 | 2022 | 7512 | 0.070 |
Why?
|
Area Under Curve | 2 | 2008 | 1635 | 0.070 |
Why?
|
Diuretics | 1 | 2009 | 612 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 638 | 0.070 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 1344 | 0.070 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1500 | 0.070 |
Why?
|
Syndrome | 2 | 2017 | 3278 | 0.070 |
Why?
|
Propensity Score | 1 | 2013 | 1918 | 0.070 |
Why?
|
Spironolactone | 1 | 2009 | 411 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 12806 | 0.060 |
Why?
|
Coronary Angiography | 2 | 2008 | 4560 | 0.060 |
Why?
|
Glucose | 1 | 2017 | 4361 | 0.060 |
Why?
|
Genotype | 2 | 2016 | 12959 | 0.060 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3381 | 0.060 |
Why?
|
Probiotics | 1 | 2008 | 377 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2006 | 338 | 0.060 |
Why?
|
Enzymes | 1 | 2006 | 261 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2014 | 39254 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2008 | 1600 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2009 | 1256 | 0.060 |
Why?
|
Alanine | 1 | 2006 | 607 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2696 | 0.060 |
Why?
|
Emergency Service, Hospital | 6 | 2008 | 7809 | 0.050 |
Why?
|
Adult | 9 | 2024 | 219847 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20048 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 709 | 0.050 |
Why?
|
United States | 5 | 2024 | 72363 | 0.050 |
Why?
|
Liver Diseases | 1 | 2011 | 1301 | 0.050 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1583 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2007 | 14656 | 0.050 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 43 | 0.050 |
Why?
|
Inflammation | 2 | 2012 | 10757 | 0.050 |
Why?
|
Weight Loss | 2 | 2024 | 2683 | 0.050 |
Why?
|
Age Factors | 2 | 2017 | 18415 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13505 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3605 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 12901 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 2063 | 0.040 |
Why?
|
Uromodulin | 1 | 2019 | 44 | 0.040 |
Why?
|
Eicosapentaenoic Acid | 1 | 2023 | 613 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 358 | 0.040 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2020 | 207 | 0.040 |
Why?
|
Niacin | 1 | 2019 | 119 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2128 | 0.040 |
Why?
|
Lung Diseases | 1 | 2008 | 1915 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 54263 | 0.040 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2020 | 600 | 0.040 |
Why?
|
Inheritance Patterns | 1 | 2019 | 340 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 42034 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 680 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14482 | 0.030 |
Why?
|
Docosahexaenoic Acids | 1 | 2023 | 912 | 0.030 |
Why?
|
Carbohydrate Metabolism | 1 | 2017 | 262 | 0.030 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.030 |
Why?
|
Animals | 7 | 2022 | 167940 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2777 | 0.030 |
Why?
|
Erythrocyte Indices | 1 | 2016 | 145 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 13967 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 398 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7468 | 0.030 |
Why?
|
Hematocrit | 1 | 2016 | 630 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 409 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2418 | 0.030 |
Why?
|
Homozygote | 1 | 2019 | 1786 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8449 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1135 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2020 | 1134 | 0.030 |
Why?
|
Smoking | 1 | 2011 | 9070 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2020 | 1152 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6771 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2020 | 989 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 22066 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1093 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1133 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 2011 | 2061 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 777 | 0.030 |
Why?
|
Quality Control | 1 | 2016 | 827 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1617 | 0.030 |
Why?
|
Survival Analysis | 1 | 2006 | 10185 | 0.030 |
Why?
|
Periodicals as Topic | 1 | 2024 | 1470 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 698 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1005 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3433 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1372 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 41317 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 69 | 0.020 |
Why?
|
Triglycerides | 1 | 2019 | 2476 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 989 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2019 | 4625 | 0.020 |
Why?
|
Drosophila | 1 | 2017 | 1492 | 0.020 |
Why?
|
Hemoglobins | 1 | 2016 | 1521 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7803 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2709 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1109 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2895 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6543 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2041 | 0.020 |
Why?
|
Cats | 1 | 2008 | 976 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22041 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3528 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2020 | 4938 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2006 | 187 | 0.020 |
Why?
|
Heart Murmurs | 1 | 2006 | 94 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5790 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2916 | 0.010 |
Why?
|
Dogs | 1 | 2008 | 3843 | 0.010 |
Why?
|
Systole | 1 | 2006 | 947 | 0.010 |
Why?
|
Proteins | 1 | 2017 | 6030 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2008 | 830 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14396 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16543 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25928 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15827 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29725 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22025 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2007 | 1208 | 0.010 |
Why?
|
Body Weight | 1 | 2008 | 4613 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8157 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5876 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 8551 | 0.010 |
Why?
|
Heart Rate | 1 | 2006 | 4169 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23363 | 0.010 |
Why?
|
Rats | 1 | 2008 | 23695 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 58673 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 80301 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81216 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 8523 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 87747 | 0.010 |
Why?
|